News

NicOx raises €100 million in two-step capital increase

Country
France

NicOx SA of France said it has raised €100 million in a two-step capital increase giving it the financial means to set up a sales force in the US to help commercialise its lead anti-inflammatory drug, naproxcinod, which is being reviewed by the FDA.

France’s Novexel to be acquired by AstraZeneca

Country
France

The value to Big Pharma of novel antibiotics has been underscored by AstraZeneca’s decision to acquire Novexel SA of France for a total cash consideration of up to $505 million. Novexel currently has two anti-infectives in Phase 2 development.

Innate Pharma raises €24.3 million in share placement

Country
France

Innate Pharma SA, a pioneer in the field of cancer immunotherapies, has raised €24.3 million gross in a share placement supported by France’s Fonds Stratégique d’Investissement and existing investors, Novo Nordisk A/S and Alta Partners.

European regulator turns back gene therapy

Country
United Kingdom

The European Medicines Agency has given a negative opinion to a proposed gene therapy developed by Ark Therapeutics Group Plc for malignant brain cancer, saying the product failed to show efficacy. Ark said it will appeal against the decision.

Silence Therapeutics to merge with Intradigm Corp of the US

Country
United Kingdom

Silence Therapeutics Plc, a company that has moved quickly to capitalise on the new science of ribonucleic acid interference (RNAi), has announced plans to merge with the privately-owned Intradigm Corp of the US, which is in the same business.

 

Merck Serono collaborates with US hospital in MS research

Country
Switzerland

Merck Serono has entered into a research collaboration in multiple sclerosis with the Brigham and Women’s Hospital in Boston, Mass, US, aimed at identifying new biomarkers and possible drug targets. Financial details were not disclosed.

Addex ends development of ADX10059 for chronic indications

Country
Switzerland

Addex Pharmaceuticals Ltd said that it is ending development of its negative allosteric modulator, ADX10059, for chronic indications including long-term treatment of gastroesophageal reflux disease (GERD) and migraine prophylaxis.